For a more personal touch, our telehealth video visits connect you with our dedicated doctors 24/7, in all 50 states, for less than $40
The return of appetite is not evidence of metabolic damage but rather the removal of pharmacological appetite suppression
They are not approved by the FDA for human use outside of clinical trials
Cons: shorter shelf life, increased risk of bacterial growth unless preservatives like benzyl alcohol are used
Canadian Family Physician Medecin De Famille Canadien 51(4):519525 Ahmed S, Amin MM, Sayed S (2023) Ocular drug delivery: a comprehensive review
This prospectively planned, pooled individual participant data cardiovascular safety meta-analysis came to the conclusion that treatment with once-weekly tirzepatide at doses of 5 mg, 10 mg, and 15 mg, with controlled treatment exposure up to 104 weeks, was not linked to an increased risk for cardiovascular events in people with T2DM across a spectrum of T2DM duration and cardiovascular risk levels